Low Vitamin D in Advanced- Stage Breast Cancer Patients
Women with early-stage breast cancer have higher vitamin D levels
TUESDAY, Oct. 17 (HealthDay News) -- Serum levels of 25-hydroxyvitamin D, or 25(OH)D, may play a role in the progression of breast cancer, according to a report published online Oct. 17 in the Journal of Clinical Pathology.
David M. Vigushin, Ph.D., of Imperial College London in the U.K., and colleagues conducted a study of 279 white women with invasive breast cancer, of whom 204 women had early-stage disease and 75 had locally advanced or metastatic disease.
To clarify the role that vitamin D may play in the progression of invasive breast cancer, measurements of circulating levels of 25(OH)D, parathyroid hormone (PTH) and calcium were taken. Among the women with early-stage disease, 25(OH)D levels were significantly higher and PTH levels were significantly lower than those of the women with advanced disease. There was no significant difference in calcium levels.
Although the study shows that vitamin D levels are lower in women with advanced-stage breast cancer than those with early-stage disease, the findings leave several questions unanswered, the authors write.
"These include the potential causes and mechanisms underlying this dysregulation of vitamin D regulation, their precise molecular consequences and the potential clinical implications of monitoring or maintaining high circulating vitamin D levels in patients diagnosed with breast cancer," they conclude.